옵션 체인은 다양한 행사가격과 만기일에 대한 Asset Entities의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Asset Entities에 대한 시장 심리를 평가합니다..

Asset Entities (NASDAQ:ASST) 주식, 옵션 체인

Asset Entities

Asset Entities Inc is an Internet company providing social media marketing, content delivery, and development and design services across Discord, TikTok, and other social media platforms. The company has developed three categories of services, which include: providing subscription upgrades to premium content on investment education and entertainment servers on Discord; co-developing and executing influencer social media and marketing campaigns for clients; and designing, developing, and managing Discord servers for clients under AE.360.DDM brand. In addition, it offers Ternary v2, a cloud-based subscription management and payment processing solution for Discord communities, which includes a suite of customer relations management tools and Stripe-verified payment processing.

Asset Entities Inc. - Class B Common Stock

Asset Entities Inc

Microsoft Corp. Co-founder Bill Gates, in a conversation with Jay Shetty, reflected on his decades-long relationship with Apple Inc. Co-founder Steve Jobs, labelling him a "genius in a way you can&#8217;t explain."
What Happened: During <a href="https://www.youtube.com/watch?v=pBRSZBtirAk">the</a> 2023 interview, Gates spoke frankly about his professional and personal history with Jobs, reminiscing about their early collaborations on the Apple II and Macintosh projects, noting, "I worked with both Jobs and Wozniak to get that done." Their paths crossed many times, with Microsoft even writing software for Jobs' later projects.
Gates also commended Apple's growth after Jobs': "It's unbelievable what a great job he did, because Apple went from being on the way to dying to being the world's most valuable company."
Pondering on Jobs' one-of-a-kind talents, Gates said, "He was just genius in a way you can&#8217;t explain&#8230; His taste in design and user interface and even his intuition about people—he was just genius." Gates contrasted these skills with his own more technical expertise.
See Also: <a href="https://www.benzinga.com/tech/25/05/45214914/steve-jobs-judged-every-idea-like-a-first-time-customer-expected-instant-clarity-and-was-brutally-direct-when-reviewing-new-ideas-said-ex-apple-engineer-behind-autocorrect">Steve Jobs Expected Instant Clarity, Judged Ideas Like A First-Time Customer, Says Former Apple Engineer Behind Autocorrect</a>
Why It Matters: Gates' comments add a new dimension to the simplistic "rivals" narrative often projected onto Jobs and him. Despite the competition between them, Gates spoke about Jobs with admiration: "In some ways he&#8217;s more singular… I don't know somebody who's just like Steve Jobs."
This is not the only time Gates has spoken highly of Jobs. In 2020, he said it would be a <a href="https://www.benzinga.com/personal-finance/25/04/44780772/bill-gates-said-its-a-gross-oversimplification-to-compare-elon-musk-to-genius-steve-jobs-you-wouldnt-walk-into-a-room-and-confu">"gross oversimplification"</a> to compare Elon Musk to "genius" Steve Jobs, remarking that "you wouldn&#8217;t walk into a room and confuse them." Gates has also confessed to <a href="https://www.benzinga.com/markets/24/10/41457050/bill-gates-once-said-he-was-so-jealous-of-apples-steve-jobs-and-labeled-him-a-genius-and-wizard-no-o">feeling &#8220;so jealous&#8221;</a> of Jobs&#8217; renowned ability to captivate people, calling it a defining trait that drove Jobs&#8217; success as a leader. Earlier this year, <a href="https://www.benzinga.com/tech/25/02/43577868/bill-gates-says-steve-jobs-once-told-him-i-wish-youd-take-acid-that-would-enhance-microsofts-product-design-more-i-envy-those-skills-im-not-in-his-league">Gates shared an anecdote</a> about how Jobs suggested that he do hallucinogenic drugs to have "more taste" when designing Microsoft products.
In 1997, as Apple faced bankruptcy, Gates intervened with a <a href="https://www.benzinga.com/personal-finance/24/10/41340693/bill-gates-saved-rival-apple-from-bankruptcy-by-investing-150-million-steve-jobs-thanked-him-pub">generous $150 million investment</a> that salvaged the company, for which Jobs thanked him publicly.
Read Next: <a href="https://www.benzinga.com/news/management/25/05/45190886/steve-jobs-warned-the-difference-between-good-and-great-software-engineers-is-50to1-admitted-firing-non-performers-was-very-painful-yet-necessary">Steve Jobs Warned The Difference Between Good And Great Software Engineers Is &#8217;50‑To‑1,&#8217; Admitted Firing Non-Performers Was &#8216;Very Painful&#8217; Yet Necessary</a>
Image Via Shutterstock

News

Tech

General

Bill Gates Called Steve Jobs A 'Genius In A Way You Can't Explain,' Says 'I Don't Know Anybody Who's Just Like Him' While Reflecting on Their Decades-Long Collaboration and Rivalry

Tredegar (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TG#NYSE">TG</a>) reported quarterly earnings of $0.10 per share. This is a 28.57 percent decrease over earnings of $0.14 per share from the same period last year. The company reported $133.63 million in sales this quarter. This is a 17.00 percent increase over sales of $114.22 million the same period last year.

Earnings

Tredegar Q1 Adj. EPS $0.10 Down From $0.14 YoY, Sales $133.63M Up From $114.22M YoY

HOFV

Trading Halt: Halt status updated at 8:25:00 AM ET: Quotation Resumption: News and Resumption Times

Barrington Research analyst Alexander Paris maintains Universal Technical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTI#NYSE">UTI</a>) with a Outperform and raises the price target from $35 to $36.

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Universal Technical, Raises Price Target to $36

Trading Halt: Halted at 8:25:00 a.m. ET - Trading Halt: Halt News Pending

The Joint Commission and Palantir Technologies announced today a long-term strategic partnership aimed at revolutionizing how healthcare organization and accreditation data are gathered and utilized. This will support healthcare organizations in benchmarking quality and improving outcomes. By leveraging Palantir's cutting-edge data analytics and artificial intelligence, this collaboration will allow both The Joint Commission and healthcare organizations to increase operational efficiency in the management of quality standards for accreditation and certification, supporting hospitals and healthcare organizations in delivering the highest – and safest – level of patient care.

PLTR

The Joint Commission And Palantir Technologies Announce Strategic Partnership To Elevate Patient Safety And Healthcare Standards

Valvoline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) affirms FY2025 Adj EPS guidance from $1.57-$1.67 to $1.57-$1.67 vs $1.63 analyst estimate. Affirms FY2025 sales outlook from $1.67 billion-$1.73 billion to $1.67 billion-$1.73 billion vs $1.74 billion estimate.

Guidance

Valvoline says, "H1 performance is strong, and we remain on track for full-year guidance."

requesting a partial stay pending appeal and partial vacatur of the Preliminary Injunction (PI) dated March 13, 2025 granted by the New York Southern District Court (SDNY) in the Company's case vs LZGI (Case No 1:24-cv-08464).
&nbsp;
The PI that the Company has been seeking to stay enjoins Genius Group from "issuing additional shares of its stock and from any manipulation of its shares, and from purchasing Bitcoin with funds from investors, funds raised from rights offerings, and funds raised from the purchase of additional shares, pending the hearing and determination of the arbitration".
&nbsp;
Further to this hearing, on May 7, 2025, the Court of Appeals ruled in the Company's favor, with the following ruling:
&nbsp;
"Appellant has made a strong showing that it is likely to succeed on the merits and suffers clear irreparable injury absent a stay, warranting a stay pending appeal. See Uniformed Fire Officers Ass'n v. de Blasio, 973 F.3d 41, 48 (2d Cir. 2020) (setting forth stay factors). Accordingly, upon due consideration, it is hereby ORDERED that the motion for a partial stay pending appeal is GRANTED and the district court's March 13 injunction against Appellant is STAYED pending the resolution of this appeal. The preliminary injunction remains in effect as to Appellees."
&nbsp;
"It is further ORDERED that the Appellant's motion for partial vacatur of the preliminary injunction, which is construed as seeking summary reversal, is DENIED. The Clerk's Office is directed to consult with the parties to set an expedited schedule for briefing and argument to be held as soon as practicable."
&nbsp;
In summary, the Court of Appeals ruling enables the Company to resume its normal operations with immediate effect, including raising funds, selling shares, buying Bitcoin and funding its operations and growth plans, pending the resolution of the appeal.
&nbsp;
Following this positive development, the Company is now focused at restructuring and rebuilding based on the considerable damages incurred by the Temporary Restraining Order (TRO) and PI over the last three months. It is also committed to recovering the damages incurred, which has increased to $250 million.
&nbsp;
As detailed in previous filings and the Company's most recent investor call, since February 14, 2025, the Company filed multiple letters and motions to the court explaining that the TRO and PI did not maintain the status quo pending arbitration, that they were based on false statements designed to defraud the court, and the intent of the filing of the TRO and PI was to extort further money from Genius. In relation to the Company's allegations of fraud and extortion, on March 31, 2024, the Company filed a lawsuit against Peter Ritz and Michael Moe as the controlling officers and directors of LZGI International, Inc ("LZG") under the Racketeer Influenced and Corrupt Organizations Act (RICO), in the United States District Court, Southern District of Florida, seeking over $450 million in damages caused by the defendants to Genius Group.
&nbsp;
Further to this ruling, the Company has instructed its lawyers to submit an updated claim in the RICO lawsuit seeking treble damages and updating the damages the Company seeks in the RICO lawsuit to $750 million.
&nbsp;
The Company remains committed to protecting itself and its shareholders through legal actions, is committed to rebuilding its education business and operations impacted by these third party actions, and rebuilding its Bitcoin Treasury.

Legal

Genius Group Secures Court Of Appeals Ruling Granting Partial Stay Of Preliminary Injunction, Allowing Immediate Resumption Of Fundraising, Share Issuance, And Bitcoin Treasury Strategy Pending Appeal, While Advancing $750M RICO Lawsuit Over Alleged Fraud And Extortion That Caused $250M In Damages

Despite mounting pressure and calls for lower interest rates, the Federal Reserve held rates steady at 4.25%-4.5% on Wednesday. This analyst anticipates that the Fed would be among the last central banks to cut interest rates, while still expecting four cuts this year.
What Happened: The Chairman and Founder of Navellier &amp; Associates, Louis Navellier, said that &#8220;Other central banks like the Bank of England and the European Central Bank are going to continue to cut rates, so we are still in the midst of a global interest rate collapse.&#8221;
This comes as the Bank of England cut its interest rates to 4.25% as widely expected by the market, on Thursday.
According to him, with other central banks cutting their interest rates, &#8220;money will slosh back to America because our rates will be higher than everybody else&#8217;s.&#8221;
&#8220;Our Fed will be the last to cut, but I&#8217;m still in the camp that they should cut four times this year,&#8221; he said.
Navellier also highlighted a positive development in the ongoing U.S.-China trade tensions. He pointed out that China has recently exempted 131 U.S. goods from tariffs, representing approximately $40 billion in trade.
This, according to Navellier, is a &#8220;thaw&#8221; in the trade dispute, a sentiment backed by the upcoming meeting between U.S. Treasury Secretary Scott Bessent and Chinese trade negotiators this weekend in Switzerland.
&#8220;We do have tariffs on autos and reciprocal tariffs against other countries, but the irony is that most reciprocal tariffs are not expected to be enacted, since most countries will be lowering their respective trade barriers and promising to buy U.S. goods,&#8221; he said.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/05/45251508/warren-buffett-falls-behind-nancy-pelosi-in-stock-market-returns-over-the-last-11-years-heres-what-data-shows">Warren Buffett Falls Behind Nancy Pelosi In Stock Market Returns Over The Last 11 Years: Here&#8217;s What Data Shows</a>
Why It Matters: Echoing concerns about a potential economic slowdown, Mohamed A. El-Erian, another prominent economist, noted on X that the Federal Reserve&#8217;s statement signaled a &#8220;higher probability of a stagflationary wind,&#8221; indicating a greater risk of both higher inflation and higher unemployment.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">As expected, the Federal Reserve left interest rates unchanged and signaled the higher probability of a stagflationary wind (that is, a greater risk of higher inflation and higher unemployment). Attention now turns to Chair Powell's press conference.<a href="https://t.co/TbPpw8GeJf">https://t.co/TbPpw8GeJf</a>…
&mdash; Mohamed A. El-Erian (@elerianm) <a href="https://twitter.com/elerianm/status/1920178852820889684?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Meanwhile, on stagflation, Ed Yardeni from Yardeni Research said, &#8220;We reckoned that the economy would remain resilient. We still think so, but Trump&#8217;s Tariff Turmoil (TTT) is stress-testing the resilience of the economy. It will probably slow economic growth and boost inflation. A short bout of stagflation is likely.&#8221;
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, rose in premarket on Thursday. The SPY was up 1.00% to $566.78, while the QQQ advanced 1.31% to $489.61, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
After Wednesday, the S&amp;P 500 index was out of the correction zone, just down 8.34% from its record high of 6,147.43 points, scaled on Feb. 19. Dow Jones was 8.78% lower than its 52-week high of 45,073.63 points, and Nasdaq 100 was 10.6% lower than its previous high of 22,222.61 points.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45280178/beyond-meat-shelves-full-year-outlook-after-7m-hit-ceo-warns-of-unforeseen-economic-headwinds-but-downplays-tariff-threat">Beyond Meat Shelves Full-Year Outlook After $7M Hit — CEO Warns Of &#8216;Unforeseen&#8217; Economic Headwinds, But Downplays Tariff Threat</a></li>
</ul>
Image Via Shutterstock

Analyst Color

Equities

Government

Macro Economic Events

Macro Notification

Market Summary

Regulations

Futures

Economics

Federal Reserve

Markets

Federal Reserve 'Will Be The Last To Cut' Rates, Says Expert Who Still Expects Four Cuts In 2025

Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) is looking for Q2 GAAP EPS of $0.16 vs $0.17 analyst estimate..

Hanesbrands Sees Q2 GAAP EPS $0.16 vs $0.17 Est

Chardan Capital analyst Daniil Gataulin maintains EyePoint Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYPT#NASDAQ">EYPT</a>) with a Buy and lowers the price target from $33 to $27.

EYPT

Chardan Capital Maintains Buy on EyePoint Pharmaceuticals, Lowers Price Target to $27

Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) raises FY2025 GAAP EPS guidance from $0.39-$0.45 to $0.42-$0.46 vs $0.38 analyst estimate..

Hanesbrands Raises FY2025 GAAP EPS Guidance from $0.39-$0.45 to $0.42-$0.46 vs $0.38 Est

Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) is looking for Q2 Adj EPS of $0.18 vs $0.19 analyst estimate. sees sales of $970.000 million vs $972.50 million analyst estimate.

Hanesbrands Sees Q2 Adj EPS $0.18 vs $0.19 Est; Sees Sales $970.000M vs $972.50M Est

CERO

CERo Therapeutics Holdings Regains Nasdaq Compliance

Rallybio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.26) by 19.23 percent. This is a 55.32 percent increase over losses of $(0.47) per share from the same period last year. The company reported $212.00 thousand in sales this quarter.

Earnings Beats

RLYB

Rallybio Q1 EPS $(0.21) Beats $(0.26) Estimate, Sales $212.00K

Hanesbrands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) affirms FY2025 Adj EPS guidance from $0.51-$0.55 to $0.51-$0.55 vs $0.51 analyst estimate. Affirms FY2025 sales outlook from $3.47 billion-$3.52 billion to $3.47 billion-$3.52 billion vs $3.50 billion estimate.

Hanesbrands Affirms FY2025 Adj EPS Guidance of $0.51-$0.55 vs $0.51 Est; Affirms FY2025 Sales Guidance of $3.47B-$3.52B vs $3.50B Est

- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4422494-1&amp;h=2101893096&amp;u=https%3A%2F%2Fwww.itn.tv%2F&amp;a=ITN">ITN</a>, the leader in automated activation technology for local TV, and <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4422494-1&amp;h=794122102&amp;u=https%3A%2F%2Fwww.magnite.com%2F&amp;a=Magnite">Magnite</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>), the largest independent sell-side advertising company, today announced a breakthrough collaboration to modernize the execution of local TV advertising, enabling advertisers to transact live linear ads from local TV stations programmatically for the first time.
The local TV advertising market is expected to reach <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4422494-1&amp;h=3463902908&amp;u=https%3A%2F%2Fbia.com%2Fpress-releases%2Flocal-tv-advertising-poised-for-growth-in-2025-led-by-legal-and-automotive-industries%2F&amp;a=%2421+billion">$21 billion</a> in the US this year. As advertiser demand for live local inventory rises, ITN and Magnite are making local TV supply easier to buy.
This collaboration builds on the successful launch of ITN's local linear SSP in late 2024. ITN's platform is built on its extensive supplier network, which includes 75 broadcast ownership groups spanning over 1,100 stations.
ITN's technology translates local linear ad supply from TV stations into biddable impressions and connects to Magnite's SpringServe ad server to combine the scale of local linear with the ease of digital automation.
The integration supports:
<ul>
<li>Real-time bidding and VAST workflows that allow advertisers to buy live local linear TV programmatically alongside streaming and online video buys.</li>
<li>A bid multiplier that forecasts impressions for one-to-many delivery channels. While most programmatic platforms focus on individual ad targeting,&nbsp;Magnite's SpringServe platform also supports linear TV delivery, allowing advertisers to easily add local linear to their media plans alongside impression-based buys.</li>
<li>A seamless back-end workflow that allows local TV stations to compete directly for advertising dollars alongside national networks and online streaming alternatives.</li>
</ul>
"Programmatic linear TV is finally happening," said Todd Watson, CEO of ITN. "Linear TV is still one of the most powerful mediums available to advertisers, but it was getting squeezed out of media plans because it was harder and more expensive to activate than its digital counterparts," Watson said. "This collaboration changes all that."
Said Matt McLeggon, SVP, Advanced Solutions at Magnite: "Local linear TV represents massive incremental reach and scale for digital advertisers – and it's a very valuable way for them to connect with audiences they may be missing. Our collaboration with ITN marries linear-focused technology with programmatic efficiency to create an ideal TV ad buying experience."
Multiple Fox television stations successfully tested programmatic transactions of ITN-supplied inventory.
"As we navigate a new era of selling video impressions, it is imperative to collaborate with those who share our forward-thinking mindset. Being the first station group to participate in programmatic transactions of ITN-supplied inventory reflects that commitment," said Tom Fleming, SVP of Sales, Fox Television Stations. "We understand the unique value our audience delivers to marketers—but we also recognize the need to make that value easier to access and act on. This platform gives our clients a streamlined, digital-like buying experience that helps us compete more effectively in today's media landscape."

Contracts

MGNI

ITN and Magnite Enters Partnership To Help Modernize Execution Of Local TV advertising

Prime Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRME#NASDAQ">PRME</a>) reported quarterly losses of $(0.40) per share which missed the analyst consensus estimate of $(0.36) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $1.45 million which beat the analyst consensus estimate of $1.05 million by 38.62 percent. This is a 146.02 percent increase over sales of $591.00 thousand the same period last year.

Earnings Misses

PRME

Prime Medicine Q1 EPS $(0.40) Misses $(0.36) Estimate, Sales $1.45M Beat $1.05M Estimate

<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="900" height="600" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/08070358/Ribolife.png" alt="" class="wp-image-12605" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/08070358/Ribolife.png 900w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/08070358/Ribolife-300x200.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/05/08070358/Ribolife-768x512.png 768w" sizes="(max-width: 900px) 100vw, 900px" /></figure>
The biopharma firm has filed for a Hong Kong IPO after already completing eight financing rounds to support its research into cutting-edge nucleotide drugs

<h4 class="wp-block-heading">Key Takeaways:</h4>
<ul>
<li>As a pioneer in gene-targeted therapy, Ribo Life has six siRNA candidate drugs undergoing clinical trials</li>
<li>It previously raised 1.8 billion yuan from industry investors and also derives income from licensing partnerships</li>
</ul>
They have been hailed as a new frontier in pharmacology: chemically synthesized drugs based on nucleic acids in the human genome.
The mRNA vaccines used during the Covid pandemic belong to this high-growth class of drugs, along with emerging treatments that can switch off potentially harmful genes in the battle against cancer. This line of research is proving popular with biopharmaceutical companies, offering the benefits of a short R&amp;D cycle and rapid drug testing process.
Now a Chinese company that has been developing RNA-based nucleotide drugs for 17 years,&nbsp;Suzhou Ribo Life Science Co. Ltd., has filed for a&nbsp;<a href="https://www1.hkexnews.hk/app/sehk/2025/107314/documents/sehk25042504214.pdf">listing</a>&nbsp;on the main board of the Hong Kong Stock Exchange to raise money to accelerate its work.
Ribo Life specializes in therapies using siRNA, or "small interfering RNA", a technique that blocks the actions of genes implicated in a host of diseases. The company boasts what it calls one of the world's largest siRNA pipelines, containing six candidate drugs aimed at cardiovascular, metabolic, liver and kidney conditions, four of which have reached Phase Two clinical trials.
RNA acts as a bridge connecting genes and proteins, while chemically modified oligonucleotides help to create drugs with prolonged potency and wide uses. &nbsp;With these advantages, nucleotide medicines have been tipped to become the third major new class of innovative remedies after small molecule and antibody drugs.
The siRNA treatments use modified nucleic acids to treat gene-specific diseases, including conditions lacking any other effective drug options, from rare genetic disorders to chronic diseases and certain cancers. According to research cited in the prospectus, growth in the global oligonucleotide market is expected to accelerate, reaching $46.7 billion in 2033 at a compound annual growth rate (CAGR) of 26.1% over a decade, with siRNA drugs accounting for approximately 40% of the market.
The prospectus describes RBD4059, one of Ribo Life's core candidate products, as the world's first and most advanced siRNA drug in clinical development for the treatment of thrombotic diseases that kill more 10 million people a year globally.
The drug is designed to inhibit the formation of blood clots while managing the counter risk of excessive bleeding, with doses needed just every three to six months, offering a superior option to traditional anticoagulant treatments, the prospectus said. The company expects to wrap up the Phase 2a clinical trial for the drug by the end of 2025.
Additionally, Ribo Life has another two key products under development targeting unhealthy levels of fat in the blood stream: RBD5044 for hypertriglyceridemia and RBD7022 for hypercholesterolemia.
Globally, the prevalence of excessive blood lipids in adults is estimated at around 40%, affecting approximately 3 billion individuals each year, the prospectus said. Those with elevated triglycerides or cholesterol, which are significant risk factors for cardiovascular and metabolic diseases, account for more than half of that total, taking the market for lipid-lowering drugs to $20.7 billion in 2023.
Ribo Life's other key drug, RBD1016, targets chronic hepatitis B and hepatitis D. The company has predicted the product will become a cornerstone therapy for hepatitis B in due course.
<h4 class="wp-block-heading">Financing treadmill</h4>
Despite the clinical potential of nucleotides, researchers must still tackle significant challenges, such as accurately targeting the drugs and avoiding harmful side effects.
Additionally, the synthesis process for nucleic acids can be complex and costly. Hence, only seven siRNA drugs have been approved globally since the first product in the category got the marketing green light in 2018.
Ribo Life does not yet have any products on the market or close to being launched. Without product revenue, the company relies on funding from its backers or income from licensing agreements with drug partners. Its revenues of 44,000 yuan ($6100) in 2023 and 142 million yuan in 2024 were achieved with the help of two large-scale licensing deals.
In December 2023, China's Qilu Pharmaceutical was granted the rights to develop, manufacture and commercialize Ribo Life's drug for high cholesterol, RBD7022, in Greater China for more than 700 million yuan in upfront and milestone payments. In the same year, Ribo Life agreed with German pharmaceutical company Boehringer Ingelheim to jointly develop therapies for hepatitis in a deal valued at more than $2 billion.
Still, the costs associated with developing innovative drugs meant the company has been reliant on its financial backers for cash. Ribo Life's R&amp;D expenses reached 315 million yuan in 2023 and 280 million yuan last year, far exceeding its revenues.
Since completing its Series A financing in 2016, Ribo Life has been constantly in the market for funds, securing investments from the likes of state-backed Advanced Manufacturing Industry Fund and prominent players such as Hillhouse Capital and China Resources Pharmaceutical Industry Fund. All in all, Ribo Life has raised 1.8 billion yuan in eight funding rounds through to Series E, reaching a post-investment valuation of around 4.87 billion yuan after its last financing foray in January this year. However, the valuation dropped to 3.58 billion yuan in February after existing shareholders transferred shares at a low price.
Ribo Life applied to list on Shanghai's Science and Technology Innovation Board in 2020 but without success. It said the proceeds from a Hong Kong listing would primarily be used to fund research into multiple drug projects and for general corporate purposes.
The company would not be the first siRNA stock to trade on the Hong Kong market.&nbsp;Sirnaomics&nbsp;(2257.HK) claimed that accolade when it listed in late 2021, trading at an initial price of HK$65.90. However, the stock has since plunged to just HK$3 to give a market capitalization of around HK$320 million, far less than Ribo Life's post-financing value. It remains to be seen whether Ribo Life can win resounding investor support with its multiple pipelines and partnership deals.

Asia

IPOs

Opinion

RNA Drug Developer Targets Fresh Funding Channel

Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) reported quarterly losses of $(0.20) per share. This is a 300 percent decrease over losses of $(0.05) per share from the same period last year. The company reported $142.00 thousand in sales this quarter. This is a 99.10 percent decrease over sales of $15.73 million the same period last year.

Silence Therapeutics Q1 EPS $(0.20) Down From $(0.05) YoY, Sales $142.00K Down From $15.73M YoY

Press Releases

Asset Entities Acquires 50% Ownership of Film, TV, Streaming, and Media Rights to Music Icon Jeff Blue's Linkin Park Story, One Step Closer: From Xero to #1: Becoming Linkin Park

TikTok Approves Asset Entities as an Official TikTok Shop Partner

Asset Entities Passes Milestone of 9,000 Members on its TikTok Shop Creator Discord Community

Media, Management And Content Delivery On Discord

Asset Entities Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1)

Asset Entities to Merge with Strive Asset Management to Form the First Publicly Traded Asset Management Bitcoin Treasury Company

STRIVE ASSET MANAGEMENT TO COMBINE WITH ASSET ENTITIES (NASDAQ: ASST) TO FORM FIRST PUBLICLY TRADED ASSET MANAGEMENT BITCOIN TREASURY COMPANY

ASST Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Asset Entities Inc. Is Fair to Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Asset Entities Inc. - ASST

ASST

Able View Global Inc. - Class B Ordinary Shares

Able View Global

Advantage Solutions Inc. - Class A Common Stock

Advantage Solutions

AirNet Technology Inc. - American Depositary Shares, each representing one ordinary shares

AirNet Technology

Boston Omaha Corporation Class A Common Stock

Boston Omaha

Cardlytics

Creative Realities

Direct Digital Holdings, Inc. - Class A Common Stock

Direct Digital Holdings

Everbright Digital Holding Limited - Ordinary Shares

Everbright Digital Hldgs

EPWK Holdings Ltd. - Class A Ordinary Shares

EPWK Holdings

Entravision Communications Corporation Common Stock

Entravision Comms

Fluent

Gambling.com Group Limited - Ordinary Shares

Gambling.com Gr

GD Culture Group

Harte-Hanks

Marchex

National CineMedia

PubMatic

QMMM Holdings Limited - Class A Ordinary Shares

QMMM Holdings

comScore

Smart Digital Group Limited - Ordinary Shares

Smart Digital Group

SPAR Group

Star Fashion Culture Holdings Limited - Class A Ordinary Shares

Star Fashion Culture

Stran & Co

WiMi Hologram Cloud Inc. - Class B Ordinary Shares

Comments

Asset Entities

Asset Entities (ASST) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌